Providers often manage chronic conditions, follow-up care, preventive services, diagnostic evaluations, and ongoing treatment plans within the same practice
FDA 503A Category 2 (April 2026) On April 15, 2026, the FDA published a 503A bulks list update
AOD-9604 primarily targets fat metabolism MOTS-c focuses on mitochondrial function and metabolic efficiency Tesamorelin increases physiologic growth hormone release and reduces visceral fat Semaglutide reduces appetite through GLP-1 signaling Tirzepatide combines GLP-1 and GIP receptor activation and currently delivers some of the most impressive weight-loss results seen in modern medicine Understanding these differences is essential when choosing the right therapy for weight loss, metabolic health, body composition, or long-term wellness goals
When used together in Dragon Pharma's formulation, these peptides work synergistically to promote rapid healing, combat inflammation, and enhance physical resilience
The presence of certain medications or supplements can impact the safety and effectiveness of MIC B12 injections
Some peptides (like growth hormone) are FDA-approved drugs